Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.
Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
Satti I. et al, (2024), The Lancet Infectious Diseases, 24, 909 - 921
Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
Satti I. et al, (2022), Nature Communications, 13
Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.
Wilkie M. et al, (2022), Scientific reports, 12
Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination
Bitencourt J. et al, (2022), Frontiers in Immunology, 12
Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults.
Riste M. et al, (2021), Vaccines, 9
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
Induction of specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination
Bitencourt J. et al, (2021)
A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates.
Tanner R. et al, (2021), NPJ vaccines, 6
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478
Factors affecting the species of Campylobacter colonizing chickens reared for meat.
Babacan O. et al, (2020), Journal of applied microbiology
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M. et al, (2020), Vaccine, 38, 779 - 789
Cytomegalovirus infection is a risk factor for tuberculosis disease in infants.
Müller J. et al, (2019), JCI insight, 4
Author Correction: The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays.
Tanner R. et al, (2019), Scientific reports, 9
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16
A CLINICAL CHALLENGE TRIAL DELIVERING AEROSOL BCG AS A CONTROLLED HUMAN INFECTION IN HEALTHY BCG-NAIVE, UK ADULTS: ESTABLISHING OPTIMAL DOSE AND EVALUATING SAFETY
Marshall JL. et al, (2019), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 101, 368 - 369
Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection.
Tanner R. et al, (2019), Frontiers in immunology, 10